reports
Relay Therapeutics to Participate in Two Upcoming Investor Conferences...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ETMorgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET The fi...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and C...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living ...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results a...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 7, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transfor...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Direct...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare ...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant F...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medi...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. ETGoldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET The fireside chats will be webcast...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: BoA Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 3:40 p.m. PTTD Cowen’s 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025 at 3:30 p.m. ET The fireside chats will be webcast live and ...
Relay Therapeutics Reports First Quarter 2025 Financial Results and Co...
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a cl...
Relay Therapeutics to Announce First Quarter 2025 Financial Results an...
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the ...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ALOT ASTRONOVA INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG PASSAGE BIO
RLAY INC.
CTGO RELAY THERAPEUTICS
TEAF CONTANGO ORE INC.
PROK ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MIO PROKIDNEY CORP.
DMA PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ADVM DESTRA MULTI ALTERNATIVE FUND
GF ADVERUM BIOTECHNOLOGIES INC.
THE NEW GERMANY FUND
INC.
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine the...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET The fireside chats will be webcast...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Finan...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage ...
- Jonathan Moreland
- Jonathan Moreland
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Co...
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under...
- Jonathan Moreland
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ETON ETON PHARMACEUTICALS
RLAY RELAY THERAPEUTICS
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BUKS BUTLER NATIONAL CORP
GLSI GREENWICH LIFESCIENCES INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM EATON VANCE INSD CALIF MUN BD FD
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulve...
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference ...
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+...
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium Company to host conference call on Wednesday, December 11, 2024 at 7am ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global L...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors Relay Therapeutics has potential to receive up to $500 million in upfront, r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.